Search Result

Results for "

MDMA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (5) Adrenergic Receptor (1) Apoptosis (5) Biochemical Assay Reagents (2) Dopamine Transporter (3) Drug Derivative (6) Drug Isomer (2) Drug Metabolite (2) Monoamine Transporter (1) PKA (5) Reactive Oxygen Species (ROS) (5) Reference Standards (1) Serotonin Transporter (3)
By Research Areas:	Cancer (5) Cardiovascular Disease (1) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (20)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0764

Bucladesine sodium Maximum Cited Publications 41 Publications Verification Dibutyryl cAMP sodium; DBcAMP sodium	PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-B0764A

Bucladesine hemicalcium Maximum Cited Publications 41 Publications Verification Dibutyryl cAMP hemicalcium; DBcAMP hemicalcium	PKA Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) hemicalcium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-B0764B

Bucladesine Dibutyryl cAMP; DBcAMP	PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-B0764G

Bucladesine sodium Dibutyryl cAMP sodium; DBcAMP sodium	PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (GMP) is a Bucladesine sodium (HY-B0764) produced by using GMP guidelines. Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-W012426

1-Piperonylpiperazine MDBP	Biochemical Assay Reagents	Neurological Disease
1-Piperonylpiperazine (MDBP) is metabolized by demethylenation and subsequent methylation to N-(4-hydroxy-3-methoxybenzyl)piperazine followedby partial glucuronidation or sulfation. 1-Piperonylpiperazine can alter the disposition and metabolism of 3,4-methylenedioxymethamphetamine (MDMA) in the brain and in peripheral organs. 1-Piperonylpiperazine can inhibit the MDMA-induced neurotoxicity .

HY-B0764R

Bucladesine sodium (Standard) Dibutyryl cAMP sodium (Standard); DBcAMP sodium (Standard)	Reference Standards PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (Standard) is the analytical standard of Bucladesine sodiumn (HY-B0764). This product is intended for research and analytical applications. Bucladesine is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-172346

*N-Hydroxy MDMA* hemioxalate** N-OH MDMA hemioxalate; FLEA hemioxalate	Drug Derivative	Neurological Disease Metabolic Disease
N-Hydroxy MDMA (N-OH MDMA) hemioxalate is an N-hydroxy analogue of 3,4-methylenedioxymethamphetamine (MDMA). N-Hydroxy MDMA hemioxalate can be rapidly metabolized to MDMA and MDA in rats, which are mainly excreted in urine, and can also be detected in hair .

HY-W725213

α-ethyl 2C-D hydrochloride BL-3912; alpha-EH DOM	Biochemical Assay Reagents	Others
α-ethyl 2C-D (BL-3912) hydrochloride is a phenethylamine and amphetamine compound. In drug discrimination studies, α-ethyl 2C-D hydrochloride can serve as a reference standard for MDMA .

HY-W506356

*2,3-MDMA* hydrochloride**	Adrenergic Receptor	Neurological Disease
2,3-MDMA hydrochloride is a noradrenalin transporter and serotonin transporter inhibitor with IC₅₀ values of 6.2 μM and 82 μM, respectively .

HY-139265

*3,4-Mdma* tert-butyl carbamate**	Drug Derivative	Neurological Disease
3,4-Mdma tert-butyl carbamate is an amphetamine.

HY-W106785

N-Benzylcyclohexylamine hydrochloride	Drug Derivative	Others
N-Benzylcyclohexylamine hydrochloride, an arylcyclohexylamine, is a cutting agent in 3,4-MDMA samples.

HY-158806

3,4-DHMA TFA 3,4-Dihydroxymethamphetamine TFA; N-Methyl-α-methyldopamine TFA; HHMA TFA	Drug Derivative	Neurological Disease
3,4-DHMA (3,4-Dihydroxymethamphetamine) TFA is an active metabolite of 3,4-MDMA .

HY-116441

4-Hydroxy-3-methoxyamphetamine hydrochloride	Drug Metabolite	Neurological Disease
4-Hydroxy-3-methoxyamphetamine hydrochloride is a metabolite of 3,4-Methylenedioxymethamphetamine (MDMA). 4-Hydroxy-3-methoxyamphetamine hydrochloride can be used for forensic analysis .

HY-186170A

S-MDMA	Drug Isomer	Neurological Disease
S-MDMA is an isomer of 4-methylenedioxymethamphetamine (MDMA) isomer. S-MDMA can promotes cortical neurons growth .

HY-W701743

3,4-Dihydroxyamphetamine hydrochloride α-Methyldopamine hydrochloride; α-MeDA hydrochloride	Drug Metabolite	Cardiovascular Disease Neurological Disease
3,4-Dihydroxyamphetamine (α-Methyldopamine) (hydrochloride) is a secondary metabolite of 3,4-Methylenedioxymethamphetamine (MDMA). 3, 4-dihydroxyamphetamine (hydrochloride) is cytotoxic to rat hepatocytes. 3, 4-dihydroxyamphetamine (hydrochloride) is also used in the study of high blood pressure .

HY-186170

R-MDMA	5-HT Receptor	Neurological Disease
R-MDMA, 4-methylenedioxymethamphetamine (MDMA) isomer, is a 5-HT2A/5-HT2C receptor antagonist with an IC₅₀ of 629 and 61.4 nM. R-MDMA promotes cortical neuron growth. R-MDMA facilitates fear extinction learning and produces antidepressant-like effects in preclinical rodent models. R-MDMA can be used for the researches of post-traumatic stress disorder and depression .

HY-186170B

(R,S)-MDMA	5-HT Receptor	Neurological Disease
(R,S)-MDMA acts as a partial agonist of 5-HT2A, 5-HT2B and 5-HT2C receptors. (R,S)-MDMA belongs to psychoactive substances. (R,S)-MDMA exhibits antidepressant activity. (R,S)-MDMA can be used for research on mental disorders such as post-traumatic stress disorder and depression .

HY-W783844

(R)-Nantenine	Drug Isomer	Neurological Disease
(R)-Nantenine ((R)-(-)-nantenine) is the levorotatory isomer of Nantenine (HY-N9141). (R)-Nantenine has high affinity and selectivity for the α1A adrenergic receptor. (R)-Nantenine can block the behavioral suppression induced by MDMA. (R)-Nantenine is mainly used for the research related to diseases caused by MDMA abuse .

HY-186169B

(R,S)-MDDMA	Serotonin Transporter Dopamine Transporter	Neurological Disease
(R,S)-MDDMA is an MDMA analog that lacks the psychostimulant effects of its parent compound. (R,S)-MDDMA still retains partial serotonin-releasing activity .

HY-172763

EDMA hydrochloride	Drug Derivative Serotonin Transporter Dopamine Transporter 5-HT Receptor	Neurological Disease
EDMA hydrochloride is a derivative of MDMA. EDMA hydrochloride is a substrate for multiple neurotransmitter transporters, including serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET). EDMA hydrochloride has 5-HT releasing activity at SERT (EC₅₀ = 117 nM) and MPP ⁺ releasing activity at DAT (EC₅₀ = 597 nM) and NET (EC₅₀ = 325 nM) .

HY-186169

R-MDDMA	5-HT Receptor Drug Derivative	Neurological Disease
R-MDDMA, 4-methylenedioxymethamphetamine (MDMA) analogue, is a 5-HT2A/5-HT2C receptor modulator. R-MDDMA shows antagonistic activity against 5-HT2A/5-HT2C with IC₅₀ values of 642 and 137 nM, and also shows partial agonist activity with EC₅₀ values of 24.5 and 14.4 nM, but does not activate 5-HT2B receptors. R-MDDMA promotes cortical neuron growth. R-MDDMA facilitates fear extinction learning and produces antidepressant-like effects in preclinical rodent models. R-MDDMA can be used for the researches of post-traumatic stress disorder and depression .

HY-W680886

6-APDB	Monoamine Transporter Serotonin Transporter Dopamine Transporter 5-HT Receptor	Neurological Disease
6-APDB is a class of monoamine neurotransmitter releaser and Monoamine Transporter modulator that exerts selective effects on human monoamine transporters and acts as a partial agonist at 5-HT₂ family receptors. For NET, 6-APDB has an IC₅₀ of 0.56 μM and a K_i of 18 μM; for SERT, it has an IC₅₀ of 2.3 μM and a K_i of 23 μM; for DAT, it has an IC₅₀ of 33 μM and a K_i of >30 μM, and affinity for rat and mouse TAAR1, with K_i values of 1.0 μM and 0.21 μM, respectively. 6-APDB inhibits norepinephrine and 5-HT reuptake, mediates the release of three types of monoamine neurotransmitters, shows a dose-dependent biphasic locomotor effect in mice, and fully substitutes the discriminative stimulus effect of *MDMA*. 6-APDB shows no significant cytotoxicity at high concentrations, and possesses empathogenic psychoactivity, potential hallucinogenic effects, and behavioral effects associated with intermittent abuse .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0764G

Bucladesine sodium Dibutyryl cAMP sodium; DBcAMP sodium	PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (GMP) is a Bucladesine sodium (HY-B0764) produced by using GMP guidelines. Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MDMA

Inhibitors & Agonists

GMP Molecules

Name
Email *

	Sorry, but the email address you supplied was invalid.